Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes

Journal of Cellular Physiology

Volumn 227, Issue 8, 2012, Pages 3001-3006

  Oberweis, Brandon ^a,b   Gragnoli, Claudia ^b,c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d Bios Biotech Multi Diagnostic Health Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2 RECEPTOR;

CONTROLLED STUDY; GLYCEMIC CONTROL; HUMAN; HYPERPROLACTINEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; PROLACTIN; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA; SEROTONIN; WEIGHT GAIN;

EID: 84860479289     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24023     Document Type: Review

References (46)

1. American Psychiatric Association. 2000. Schizophrenia. Washington DC: American Psychiatric Association.
2. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. 1997. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9: 1-17.
3. Boden G. 1996. Fatty acids and insulin resistance. Diabetes Care 19: 394-395.
4. Brejle TCSD, Lacy PE, Ogren L, Talamantes F, Robertson M, Friesen HG, Sorenson RL. 1993. Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: Implication for placental lactogen regulation of islet function during pregnancy. Endocrinology 132: 879-887.
5. Dwyer DS, Donohoe D. 2003. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75: 255-260.
6. Efron HY, Balter AM. 1966. Relationship of phenothiazine intake and psychiatric diagnosis to glucose level and tolerance. J Nerv Ment Dis 142: 555-561.
7. Frantz AG. 1978. Prolactin. N Engl J Med 298: 201-207.
8. Freeman ME, Kanyicska B, Lerant A, Nagy G. 2000. Prolactin: Structure, function, and regulation of secretion. Physiol Rev 80: 1523-1631.
9. Gartside SE, Cowen PJ. 1990. Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. Eur J Pharmacol 179: 103-109.
10. Gitlin MJ. 1994. Psychotropic medications and their effects on sexual function: Diagnosis, biology, and treatment approaches. J Clin Psychiatry 55: 406-413.
11. Gudelsky GA. 1981. Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology 6: 3-16.
12. Haddad PM, Wieck A. 2004. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 64: 2291-2314.
13. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF. 1999. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care 22: 562-568.
14. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. 1993. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatr 162: 80-86.
15. Hajduch E, Rencurel F, Balendran A, Batty IH, Downes CP, Hundal HS. 1999. Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J Biol Chem 274: 13563-13568.
16. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. 2000. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatr 157: 975-981.
17. Howes OD, Kapur S. 2009. The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr Bull 35: 549-562.
18. Huang C, Snider F, Cross JC. 2009. Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. Endocrinology 150: 1618-1626.
19. Jonnakuty C, Gragnoli C. 2008. What do we know about serotonin? J Cell Physiol 217: 301-306.
20. Karan RSPR. 2000. D2 and 5HT2 receptors: Relevance to antipsychotic drugs. Indian J Pharmacol 32: 187-191.
21. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. 2001. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia. J Clin Psychiatr 62: 92-100.
22. Langer GSE. 1997. Dopaminergic factors in human prolactin regulation: Effects of neuroleptics and dopamine. Psychoneuroendocrinology 2: 373-378.
23. Leysen JE, Janssen PM, Megens AA, Schotte A. 1994. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatr 55: 5-12.
24. Liebzeit KA, Markowitz JS, Caley CF. 2001. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 11: 25-32.
25. Lowy MT, Meltzer HY. 1988. Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. Biol Psychiatr 23: 818-828.
26. Meaney AM, O'Keane V. 2002. Prolactin and schizophrenia: Clinical consequences of hyperprolactinaemia. Life Sci 71: 979-992.
27. Meltzer HY, Simonovic M, Gudelsky GA. 1983. Effects of pirenperone and ketanserin on rat prolactin secretion in vivo and in vitro. Eur J Pharmacol 92: 83-89.
28. Molitch ME. 2005. Medication-induced hyperprolactinemia. Mayo Clin Proc 80: 1050-1057.
29. Newman SC, Bland RC. 1991. Mortality in a cohort of patients with schizophrenia: A record linkage study. Can J Psychiatr 36: 239-245.
30. Parsons JA, Brelje TC, Sorenson RL. 1992. Adaptation of islets of Langerhans to pregnancy: Increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology 130: 1459-1466.
31. Petryk A, Fleenor D, Driscoll P, Freemark M. 2000. Prolactin induction of insulin gene expression: The roles of glucose and glucose transporter-2. J Endocrinol 164: 277-286.
32. Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M. 1994. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatr 35: 151-163.
33. Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG. 1976. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5: 273-282.
34. Ryan MC, Collins P, Thakore JH. 2003. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatr 160: 284-289.
35. Schindler C, Darnell JE Jr. 1995. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 64: 621-651.
36. Seeman P. 2002. Atypical antipsychotics: Mechanism of action. Can J Psychiatr 47: 27-38.
37. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. 2002. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatr 159: 561-566.
38. Sorenson RL, Brelje TC. 2009. Prolactin receptors are critical to the adaptation of islets to pregnancy. Endocrinology 150: 1566-1569.
39. Sorenson RL, Johnson MG, Parsons JA, Sheridan JD. 1987. Decreased glucose stimulation threshold, enhanced insulin secretion, and increased beta cell coupling in islets of prolactin-treated rats. Pancreas 2: 283-288.
40. Sorenson RL, Stout LE. 1995. Prolactin receptors and JAK2 in islets of Langerhans: An immunohistochemical analysis. Endocrinology 136: 4092-4098.
41. Stahl S. 2003. Describing an atypical antipsychotic: Receptor binding and its role in pathophysiology. Prim Care Companion J Clin Psychiatr 5: 9-13.
42. Tomita T. 1999. Immunocytochemical localization of glucose transporter-2 (GLUT-2) in pancreatic islets and islet cell tumors. Endocr Pathol 10: 213-221.
43. Tuomisto J, Mannisto P. 1985. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 37: 249-332.
44. Turkington RW. 1972. Prolactin secretion in patients treated with various drugs: Phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med 130: 349-354.
45. Van de Kar LD. 1991. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol 31: 289-320.
46. Veldhuis JD, Johnson ML. 1988. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: Circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab 67: 116-123.